Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA User Fee Performance Metrics Revealed

You may also be interested in...



ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five

The finalized generic drug user fee agreement would clear most of the ANDA application backlog by the end of the first program cycle.

ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five

The finalized generic drug user fee agreement would clear most of the ANDA application backlog by the end of the first program cycle.

ANDA User Fee Agreement Expected To Be Finished in Early September

FDA wants the commitment letter and draft legislation ready for internal clearance by Sept. 9.

Topics

UsernamePublicRestriction

Register

PS053752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel